ACURATE neo2™ Post Market Clinical Follow up Study
← catalyst calendarSponsored by Boston Scientific Corporation (industry) · BSX — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
250actual
Sites
19
Countries
Denmark, Germany, Italy +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-12-16 | actual | When the study began enrolling |
| Primary completion | 2022-03-09 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2020-12-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-06-25 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Aortic Valve Stenosis
- Aortic Valve Calcification
- Aortic Diseases
Intervention
- Device: Transcatheter Aortic Valve Implantation/Replacement
Primary outcomes
what the primary-completion date above is the date OFPrimary Safety Endpoint:
measured 30 days
Primary Imaging Endpoint:
measured 30 days
Publications
- PMID 37982152 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · BSX's whole pipeline · Catalyst calendar · Every registered study · What changed